Enlarge / PURDUE PHARMA, STAMFORD, CT, UNITED STATES – 2019/09/12: Members of P.A.I.N. (Prescription Addiction Intervention Now) and Truth Pharm staged a protest on September 12, 2019 outside Purdue Pharma headquarters in Stamford, over their recent controversial opioid settlement.Getty | Erik McGregor

Lawyers for OxyContin-maker Purdue Pharma filed a new complaint late Wednesday threatening that the companys mega-rich owners, the Sackler family, could pull out of a proposed multi-billion-dollar opioid settlement deal if a bankruptcy judge doesnt shield the family from outstanding state lawsuits.

Purdues lawyers argue that if the lawsuits continue, the Sacklers will have to waste “hundreds of millions of dollars” on legal costs that could otherwise go to claimants in the settlement. The family's lawyers added that in that event, the family “may be unwilling—or unable—to make the billions of dollars of contributions” to the proposed settlement.

State attorneys general, however, argue that the tactic is yet another move designed to shield the Sacklers and their ill-gotten wealth.

This filing isnt a surprise. Its yet another effort by Purdue to avoid accountability and shield the Sackler family fortune, and we will be opposing it,” Maura Healey, the attorney general of Massachusetts, told the New York Times.

Dubious deal

Purdue Pharma filed for Chapter 11 bankruptcy protections Sunday, September 15, as part of a proposed global deal to settle around 2,000 lawsuits, mostly from state and local governments. The complaints are over Purdues alleged role in fueling the epidemic of opioid addiction and overdoses with its aggressive and misleading marketing of highly addictive pain killers.

The epidemic killed nearly 400,000 Americans between 1999 and 2017, according to the Centers for Disease Control and Prevention. On average, 130 Americans die each day from an opioid overdose.

Purdues lawyers say that the proposed settlement deal will value between $10 billion to $12 billion in time. Purdue would be restructured to a “public benefit trust” while turning over assets and providing addiction treatment and anti-overdose drugs. The deal involves the Sackler family giving up ownership of the company and kicking in at least $3 billion of their own funds to the settlement. Their contribution could potentially be as high as $4.5 billion, depending on what they get from the sale of their international company, Mundipharma.

Purdue is estimated to have made more than $35 billion from OxyContin, and the Sacklers have an estimated family fortune of $13 billion, largely thought to be from Purdues OxyContin profits.

Thousands of municipal governments and nearly two dozen states have tentatively agreed to the deal, while around two dozen other states involved are against it.

Benefits and risks

The bankruptcy filing automatically protects Purdue Pharma from civil suits, but cases brought by states are an exception and could potentially be allowed to continue. Purdue has asked that they be halted while the settlement is worked out.

The Sacklers, who have not filed for bankruptcy, are not entitled to any such protections from ongoing litigation. However, it is possible that the judge will grant that.

Melissa Jacoby, a bankruptcy law expert at the University of North Carolina at Read More – Source


Please enter your comment!
Please enter your name here